The global Contract Research Organization (CRO) market is on track to nearly double, from USD 55.84 billion in 2024 to USD 105.73 billion by 2033. That scale is not driven by preference. It reflects how structurally dependent modern drug development has become on external clinical execution partners.
Bringing a new therapy from an Investigational New Drug (IND) filing to regulatory approval typically takes 10 to 15 years. Development costs routinely exceed $1 billion per asset. As trial complexity grows and regulatory requirements tighten across jurisdictions, pharma and biopharmaceutical sponsors rely on CROs to absorb the operational, scientific, and compliance demands that internal teams cannot efficiently scale.
This blog examines what CROs actually do in global drug development, where they have the most impact, and what distinguishes a CRO capable of executing at that level.
How CROs Fit Into the Global Drug Development Process?
Drug development does not move in a straight line. It involves overlapping workstreams across regulatory, clinical, scientific, and operational domains. These often run simultaneously across multiple countries.
CROs absorb these workstreams when sponsors lack the operational depth to manage them across multiple countries. Under ICH-GCP E6(R2), a CRO can assume any or all of the sponsor’s trial-related duties. The sponsor retains ultimate accountability for data integrity and participant safety.
In global development specifically, CROs address three structural challenges that internal teams rarely handle efficiently:
- Regulatory fragmentation: Each country has distinct ethics, submission, and import approval requirements.
- Recruitment bottlenecks: Patient access and enrollment performance vary widely by geography, indication, and site network depth.
- Operational coordination: Running monitoring, safety, data, and logistics across time zones requires dedicated infrastructure.
For sponsors seeking a full-service model, DRK Research is one example of a CRO structured around end-to-end Phase II and Phase III trial execution. Their model covers site feasibility, multi-country regulatory submissions, hybrid monitoring, pharmacovigilance, and Clinical Study Report (CSR) preparation under a single operational framework aligned with ICH-GCP and EMA/FDA standards.
What CROs Actually Manage Across the Trial Lifecycle?
A CRO’s scope is defined by the agreement with the sponsor. Full-service CROs assume ownership of the entire study lifecycle. Functional Service Providers (FSPs) deliver specific capabilities within sponsor-controlled infrastructure.
The following table outlines the core functions CROs manage across development stages:
| Trial Stage | CRO Functions |
| Pre-study | Protocol review, site feasibility, budget planning, and investigator training. |
| Study start-up | Ethics and IRB submissions, regulatory approvals, IMP import, TMF setup. |
| Recruitment | Site initiation, patient enrollment support, and recruitment strategy execution. |
| Maintenance | On-site and centralized monitoring, SAE management, and QA visits. |
| Closeout | Last patient visit procedures, IMP reconciliation, and site closeout. |
| Reporting | Database lock, statistical analysis, CSR preparation, and medical writing. |
The model a sponsor chooses depends on internal capacity, trial complexity, and the level of operational oversight they intend to retain.
Where CROs Have the Most Impact in Global Trials?
Only approximately 12.9% of drug candidates that enter clinical trials ultimately receive FDA approval. A significant portion of late-stage failures stems from operational execution gaps, not scientific inadequacy. This is precisely where CRO capabilities determine outcomes.
1. Study Start-Up and Regulatory Navigation
Study start-up (SSU) is the phase most prone to delays in multinational trials. Regulatory authority approvals, ethics committee submissions, and drug import licensing all vary by country. Delays at this stage compress the recruitment window and escalate costs before a single patient is enrolled.
CROs with established local regulatory relationships reduce SSU timelines. Their familiarity with import logistics, tiered ethics processes, and country-specific submission formats prevents cascading delays.
2. Patient Recruitment Across Geographies
Enrollment failure is the most common reason clinical trials stall or terminate. Site selection quality, investigator engagement, and protocol accessibility are the variables that separate high-performing recruitment from chronic underenrollment.
CROs contribute through:
- Site feasibility models that predict enrollment rates by geography.
- Established investigator and site networks from prior trials.
- Recruitment strategies adapted to the local context and patient population.
- Decentralized Clinical Trial (DCT) tools, including telemedicine, remote visits, and eConsent, to reduce dropout.
3. Clinical Monitoring and Risk-Based Oversight
Monitoring ensures adherence to protocols, data accuracy, and compliance with patient safety standards at the site level. The industry has moved toward hybrid monitoring models. These combine traditional on-site visits with centralized, data-driven oversight.
Centralized monitoring uses digital dashboards and predictive analytics to detect protocol deviations and data outliers in real time. It reduces per-visit costs and enables faster corrective action.
Risk-based monitoring (RBM), described in ICH-GCP E6(R2) and supported by both FDA and EMA guidance, is the current standard for trial oversight. CROs with mature RBM frameworks deliver earlier risk detection and stronger sponsor visibility than volume-based site visit models.
4. Safety Management and Pharmacovigilance
Adverse event management is a regulatory obligation, not an administrative function. Documentation gaps or reporting delays can result in regulatory submission failures or clinical holds.
CROs supporting pharmacovigilance provide:
- End-to-end adverse event (AE) and Serious Adverse Event (SAE) intake, assessment, and reporting.
- SUSAR (Suspected Unexpected Serious Adverse Reaction) submissions within regulatory timeframes.
- Signal detection and ongoing risk-benefit evaluation.
- Pharmacovigilance (PV) system maintenance aligned with FDA and EMA expectations.
5. Data Management and Biostatistics
Clean, audit-ready data is the foundation of every regulatory submission. CRO data management services cover:
- Electronic Data Capture (EDC) system design and validation.
- Data cleaning protocols and query resolution.
- Statistical Analysis Plan (SAP) development and execution.
- Database lock and Clinical Study Report (CSR) preparation.
CROs using validated EDC systems and automated query workflows achieve faster database locks. This directly compresses overall trial timelines.
Why Global Trials Require CROs with Local Execution Depth?
A CRO with only centralized delivery capability and no in-country presence consistently underestimates approval timelines. It also underperforms on recruitment projections and site performance.
This gap is most acute in regions where regulatory approval sequences are long, ethics board timelines are unpredictable, or investigational product (IP) import requires multiple clearance stages. CROs that have managed trials in these environments carry institutional knowledge that a centralized team working from secondary sources cannot replicate.
Effective multi-country trial management depends on:
- Knowledge of country-specific regulatory authority submission requirements.
- Established ethics committee relationships and realistic submission timelines.
- Experience with drug import procedures, including cold-chain and customs logistics.
- Understanding of site performance variability and standard-of-care differences by geography.
- Cultural and language familiarity that supports investigator engagement and patient retention.
CROs with genuine on-ground regional experience provide more accurate feasibility assessments. They resolve mid-study operational issues faster and maintain recruitment momentum across diverse markets. Sponsors that overlook this dimension during vendor selection often encounter the gap late in the study, when corrective action is most disruptive.
How to Evaluate a CRO for Global Drug Development?
Vendor selection based only on cost and service lists misses the execution variables that determine trial success. The difference between a CRO that delivers on schedule and one that does not often comes down to regional delivery depth, not stated capability.
Sponsors should assess CRO partners across the following dimensions:
| Evaluation Dimension | What to Assess |
| Regulatory experience | Jurisdictions navigated the approval timeline benchmarks. |
| Site network quality | Pre-qualified sites vs. built per study |
| Monitoring approach | RBM integration, hybrid vs. on-site only |
| Technology stack | Validated eClinical platforms in active use |
| Safety discipline | SUSAR submission timelines, PV system structure |
| Therapeutic expertise | Relevant indication and phase experience |
| End-to-end capability | SSU through CSR under one operational contract. |
Fragmented vendor ecosystems introduce coordination risk. When monitoring, data, safety, and biostatistics are managed separately, issue resolution slows, and total study cost rises. A single CRO acting as the operational command center reduces handoff errors and provides clearer accountability across the full trial lifecycle.
Sponsors evaluating CROs for global programs should also confirm how the CRO handles scope changes, protocol amendments, and budget deviations. These are not edge cases. They are standard features of late-phase development. A CRO that has pre-built contingency pathways for these scenarios delivers materially better outcomes than one that addresses them reactively.
Conclusion
Contract Research Organizations are a structural component of global drug development. Each function they manage, from regulatory navigation and recruitment to monitoring, safety, and data reporting, directly affects whether a trial reaches submission on time and to standard.
Sponsors that evaluate CRO partners on operational depth, regulatory experience, end-to-end capability, and regional presence are better positioned to execute complex global trials. As pipelines expand in geographic scope and scientific complexity, the quality of a CRO partnership increasingly determines how efficiently an investigational therapy reaches the patients who need it.
